Evidence map›Paper›PMID 41685891›Full record

ArticleAntimicrobial agents and chemotherapy2026

Optimization strategies for voriconazole dosing in pediatric populations: integrating therapeutic indications and age-stratified pharmacokinetics.

Yidan Zhu, Jinxia Zhao, Jiali Chen, Yiru Gong, Nan Guo, Yinyu Zhao, Yuanyuan Li, Jialu Bian, Xuchen Song, Yuxuan Yao and 3 more

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yidan Zhu *Department of Pharmacy, Peking University People's Hospital, Beijing, China.ORCID 0009-0009-2122-9991
Jinxia Zhao *Department of Pharmacy, Peking University People's Hospital, Beijing, China.
Jiali ChenDepartment of Pharmacy, Peking University People's Hospital, Beijing, China.
Yiru GongDepartment of Pharmacy, Peking University People's Hospital, Beijing, China.
Nan GuoDepartment of Pharmacy, Peking University People's Hospital, Beijing, China.
Yinyu ZhaoDepartment of Pharmacy, Peking University People's Hospital, Beijing, China.
Yuanyuan LiDepartment of Pharmacy, Peking University People's Hospital, Beijing, China.
Jialu BianDepartment of Pharmacy, Peking University People's Hospital, Beijing, China.
Xuchen SongDepartment of Pharmacy, Peking University People's Hospital, Beijing, China.
Yuxuan YaoDepartment of Pharmacy, Peking University People's Hospital, Beijing, China.
Xingxian LuoDepartment of Pharmacy, Peking University People's Hospital, Beijing, China.
Xiaohong ZhangDepartment of Pharmacy, Peking University People's Hospital, Beijing, China.
Lin HuangDepartment of Pharmacy, Peking University People's Hospital, Beijing, China.ORCID 0000-0003-3264-1374

Funding

Beijing Municipal Natural Science Foundation 7192218Beijing Municipal Natural Science Foundation 7242210
6 · The paper itself

Abstract

There is limited evidence on the recommended voriconazole (VCZ) concentration ranges for prophylactic versus therapeutic use, and the factors influencing individualized dosing in young children remain insufficiently characterized. This retrospective study analyzed the clinical data from pediatric patients (2-17 years) at Peking University People's Hospital from September 2020 to December 2024. The aim was to define optimal concentration thresholds for prophylaxis and treatment and identify sources of pharmacokinetic variability across age groups to support individualized dosing in children. In the exposure-effect study, VCZ trough concentration (C

Indexed as

Antifungal AgentsVoriconazoleAdolescentAge FactorsChildChild, PreschoolCytochrome P-450 CYP2C19FemaleHumansMaleRetrospective StudiesAntifungal AgentsCytochrome P-450 CYP2C19Voriconazoleage groupschildrencut off valueinvasive fungal diseasepharmacokineticstherapeutic drug monitoringtrough concentrationvoriconazole

Identifiers

PMID41685891
PMCPMC12959138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.